PolyPid (PYPD) Receivables - Other (2019 - 2026)
PolyPid (PYPD) posted Receivables - Other of $661000.0 for Q2 2022, down 70.1% sequentially from $2.2 million in Q4 2021, and down 29.46% YoY from $937000.0 in Q2 2021.
PolyPid (PYPD) Receivables - Other (2019 - 2026) Analysis & Trends
PolyPid has reported Receivables - Other for 4 years, with the latest figure at $661000.0 in Q2 2022.
- Quarterly Receivables - Other fell 29.46% year-over-year to $661000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $661000.0 (down 29.46% YoY) and the FY2021 annual result came in at $2.2 million, down 5.27% from the prior year.
- Receivables - Other declined to $661000.0 in Q2 2022 per PYPD's latest filing, from $2.2 million in the prior quarter.
- Over five years, Receivables - Other peaked at $2.5 million in Q3 2020 and troughed at $417000.0 in Q4 2019.
- A 4-year average of $1.3 million and a median of $1.1 million in 2021 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2020 and 2022: Receivables - Other soared 459.71% in 2020, then fell 29.46% in 2022.
- Over 4 years, Receivables - Other stood at $417000.0 in 2019, then jumped by 459.71% to $2.3 million in 2020, then declined by 5.27% to $2.2 million in 2021, then sank by 70.1% to $661000.0 in 2022.
- According to Business Quant data, Receivables - Other over the past three periods registered $661000.0, $2.2 million, and $937000.0 for Q2 2022, Q4 2021, and Q2 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | PolyPid | 112.52 Mn | 105.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 351,000.00 |
| Mar 31, 2026 | 351,000.00 |
| Dec 31, 2025 | 995,000.00 |
| Dec 31, 2025 | 995,000.00 |
| Sep 30, 2025 | 609,000.00 |
| Sep 30, 2025 | 609,000.00 |
| Jun 30, 2025 | 351,000.00 |
| Jun 30, 2025 | 351,000.00 |
| Mar 31, 2025 | 568,000.00 |
| Mar 31, 2025 | 568,000.00 |
| Dec 31, 2024 | 764,000.00 |
| Dec 31, 2024 | 764,000.00 |
| Sep 30, 2024 | 750,000.00 |
| Sep 30, 2024 | 750,000.00 |
| Jun 30, 2024 | 268,000.00 |
| Jun 30, 2024 | 268,000.00 |
| Mar 31, 2024 | 471,000.00 |
| Mar 31, 2024 | 471,000.00 |
| Dec 31, 2023 | 458,000.00 |
| Dec 31, 2023 | 458,000.00 |